Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer

This study indicates that temozolomide has limited activity in mCRC selected by MGMT hypermethylation, and show for the first time that tumor MGMT methylation can change from diagnosis, decaying after several lines of treatments. This result points out the need to test baseline tumor biopsy or plasma in order to refine target selection in trials with alkylating agents performed in this setting.

from Cancer via ola Kala on Inoreader http://ift.tt/1VIxgXI
via IFTTT